Google, Biogen team up on MS research: report

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec ($BIIB) will team up with online overlord Google ($GOOG) to sift through a mountain of data on the topic, according to a report from Bloomberg. The big goal for Biogen, a leader in the field, is to get a better idea of why some patients see the disease progress so much faster than others. And if it's successful, they could get information that will help guide prescribing existing drugs as well as develop new ones. This is Google X labs' second big pharma collaboration. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.